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Abstract
Background: Middle East Respiratory Syndrome coronavirus (MERS-CoV) is an emerging viral pathogen that causes
severe morbidity and mortality. Up to date, there is no approved or licensed vaccine or antiviral medicines can be
used to treat MERS-CoV-infected patients. Here, we analyzed the antiviral activities of resveratrol, a natural
compound found in grape seeds and skin and in red wine, against MERS-CoV infection.
Methods: We performed MTT and neutral red uptake assays to assess the survival rates of MERS-infected Vero E6
cells. In addition, quantitative PCR, western blotting, and immunofluorescent assays determined the intracellular
viral RNA and protein expression. For viral productivity, we utilized plaque assays to confirm the antiviral properties
of resveratrol against MERS-CoV.
Results: Resveratrol significantly inhibited MERS-CoV infection and prolonged cellular survival after virus infection.
We also found that the expression of nucleocapsid (N) protein essential for MERS-CoV replication was decreased
after resveratrol treatment. Furthermore, resveratrol down-regulated the apoptosis induced by MERS-CoV in vitro.
By consecutive administration of resveratrol, we were able to reduce the concentration of resveratrol while
achieving inhibitory effectiveness against MERS-CoV.
Conclusion: In this study, we first demonstrated that resveratrol is a potent anti-MERS agent in vitro. We perceive
that resveratrol can be a potential antiviral agent against MERS-CoV infection in the near future.
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Background
Middle East Respiratory Syndrome (MERS) is a viral
respiratory illness caused by a novel coronavirus
(MERS-CoV) which was identified in Saudi Arabia in
2012 [1, 2]. Up to December 2016, the mortality rate
of MERS patients is 35.4% with 652 deaths out of 1842
confirmed cases [3]. There is still no effective anti-
MERS medicine or vaccine commercially available in
the market. One previous study showed that stilbene deriv-
atives could contain antiviral activities against Severe Acute
Respiratory Syndrome Coronavirus (SARS-CoV) [4]. As a
result, we tested whether a natural stilbene derivative,
resveratrol (trans-3, 5, 4′-trihydroxystilbene) inhibits
the MERS-CoV infection in this study. Resveratrol
exists widely in different plants, including grape (Vitis
vinifera), Huzhang (Polygonum cuspidatum) and cran-
berry (Vaccinium macrocarpon)[5]. In the past, resvera-
trol was demonstrated to decrease the production of
nitric oxide in tissue, and thereby reduce inflammation
[6–8]. Resveratrol also acts as an antioxidant to remove
free radicals [9, 10], thus restrains tumor growth [11]
and even age-related diseases [12, 13]. Resveratrol also
inhibits STAT3 signaling pathway [14], the mTOR sig-
naling [15], and the hedgehog signaling pathway [16].
Furthermore, resveratrol reportedly constrains infec-
tions caused by multiple pathogens, such as Helicobac-
ter pylori [17], Staphylococcus aureus [18] or
Toxoplasma gondii [19]. Interestingly, resveratrol has
been demonstrated to exert antiviral effects against
various viral infections, including Epstein-Barr virus
(EBV) [20, 21], enterovirus 71 (EV71) [22], and herpes
simplex virus (HSV) [23], as well as respiratory viral in-
fections caused by influenza [24], respiratory syncytial
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virus (RSV) [25, 26], and rhinovirus [27]. However, it
remains unknown whether resveratrol can inhibit
MERS-CoV infection. In this study, we evaluated the
antiviral effectiveness of resveratrol against MERS-CoV
with an in vitro model.
Methods
Viral infection
Vero E6 cells (ATCC® Number: CRL-1586™) were
planted on culture plates with 10% of fetal bovine serum
(FBS) in DMEM for overnight before viral infection.
MERS-CoV (HCoV-EMC/2012) was diluted to multipli-
city of infection (M.O.I.) 0.1 with 2% FBS/DMEM and
replaced the culture media in plates.
MTT assay
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) can be reduced into formazan with pur-
ple color by cellular oxidoreductase as an indicator to
access cell metabolism [28]. Briefly, Vero E6 cells were
cultured on 96 well plates for overnight before adminis-
trating virus and resveratrol. After 48 hours incubation,
supernatant was replaced with new culture medium and
add 20 μL of 5 mg/mL MTT solution in each well. Plates
were incubated at 37 °C for 1 hour before removing
MTT-containing medium. Extract formazan with MTT
solvent, which consists of 4 mM HCl and 0.1% Nondet
P-40 (NP40) in isopropanol followed by measuring the
level of purple formazan with ELISA reader (Spectra-
Max Plus 385, Molecular Devices®, USA) at wavelength
570 nm. The readouts obtained from MTT assay were
further normalized to the value of uninfected cells
where the value was set to 100%.
Neural red uptake (NRU) assay
Cells were cultured on 96-well plate and infected by virus
with or without treatment of resveratrol for 48 hours be-
fore performing NRU assay. The culture medium were re-
moved and each well was added to 100 μL of 0.01% (w/v)
neutral red in DMEM followed by incubating the plates at
37 °C, 5% CO2 for 1 hour. Neutral red/DMEM was re-
moved and plates were washed twice with PBS. Neutral
red dye was extracted with 100 μL/well of Sorensen Cit-
rate Buffer and the plates was gently shaken for 5 min.
The recovered neutral red dye was quantified by ELISA
reader (SpectraMax Plus 385, Molecular Devices®, USA) at
wavelength 540 nm. The results obtained were further
normalized to the average readouts of tissue control
groups where cell viability was set at 100%.
Plaque assay
Vero E6 cells were planted in 12 well plates for over-
night before conducting plaque assays. Viral samples
were 10-fold serial diluted with MEM and added into
cells. Cells were incubated with viral samples for one
hour and rocked plates for every 15 min. After incuba-
tion, the inoculums were removed and cells were washed
in PBS. MEM containing 1.5% agarose was then added
to cells as overlay medium. Plates was incubated at 37 °C,
5% CO2 for 3 days after overlay medium was solidified
and fixed directly with 0.2% crystal violet solution before
counting plaques.
Immunofluorescent assay
Vero E6 cells were seeded on 8-well chamber slides. In-
fected cells (treated with or without resveratrol) were
first fixed in 4% paraformaldehyde for 15 minutes and
then permeablized with 0.1% Triton X-100 for 10 mins.
After 30 minutes blocking with 7.5% BSA at 37 °C, cells
were immunostained with an anti-MERS-CoV N anti-
body (Sino Biological Inc., China) (1:500 dilution) at 4 °C
overnight. After three washes with PBS, cells were then in-
cubated with 1:1000 dilution of Alex Fluor® 568 anti-
rabbit secondary antibody (Thermo Fisher, USA) for
1 hour. Cells were then washed three times in PBS with
DAPI being added during the second wash. MERS nucleo-
capsid expression was examined by confocal microscope
(LSM-700, Zeiss, Germany). For intracellular staining of
MERS nucleocapsid protein, the protocol is similar to im-
munofluorescent assay for confocal microscope except the
blocking buffer was 10% horse serum in 0.05% PBS-
triton X100 and the secondary antibody was IRDye
800CW (Li-Cor®) with 1: 10,000 dilution in PBS.
Quantitative real-time PCR
Total RNA samples of Vero E6 cells with or without
MERS infection were isolated by RNeasy Mini kit (Qia-
gen®, Germany) according to the manufacturer’s instruc-
tions. Reverse transcription and PCR amplification were
carried out with iTaq™ Universal One-Step RT-qPCR kit
(Bio-rad®, USA) according to the manufacturer’s instruc-
tions. Real-time PCR was conducted by using StepOne-
Plus™ Real-Time PCR System (Appliedbiosystem®, USA)
along with the following primer pairs: GAPDH-F: 5′-G
AAGGTGAAGGTCGGAGTC-3′, GAPDH-R: 5′-GAAG
ATGGTGATGGGATTTC-3′ [29], MERS-CoV-F: 5′-CC
ACTACTCCCATTTCGTCAG MERS-CoV-R: 5′-CAG-
TATGTGTAGTGCGCATATAAGCA [30]. Each MERS
RNA level defined as viral yield l was normalized with
each GAPDH RNA level and relatively compared to
MERS-CoV groups at 24 and 48 h.p.i. respectfully as
relative RNA levels.
Results
Resveratrol reduced the cell death caused by MERS-CoV
To investigate the anti-MERS-CoV effect of resveratrol,
we directly treated MERS-CoV infected Vero E6 cells
with different concentrations of resveratrol. Cells were
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infected with MERS-CoV at M.O.I. of 0.1. After 48 hours,
we imaged the cellular morphology via microscopy and
measured cell proliferation by MTT assay, cell viability
by neutral red uptake (NRU) assay, and cytotoxicity
levels by lactate dehydrogenase (LDH) assay. Resveratrol
at 250 and 125 μM seems to alleviate the monolayer de-
struction of the Vero E6 cells infected by MERS-CoV
(Fig. 1). Results from MTTassays (Fig. 1a) and NRU assays
(Fig. 1b) showed that resveratrol can reduce the cell death
induced by MERS-CoV infection in the concentration
range from 250–125 μM. Also, resveratrol-treated groups
revealed less cytotoxicity by LDH assay after MERS-CoV
infection (Fig. 1c) and the cytotoxicity profiles correlated
well with that of cell proliferation and cell viability assays.
To determine if the observed antiviral effect by resveratrol
was due to its cytotoxicity, we performed LDH assay for
resveratrol treatment only. Figure 1d showed that resvera-
trol caused limited cytotoxicity to Vero E6 cells. Even at
the highest concentration of 250 μM, the cytotoxicity was
no more than 25%. In consistence, the cytotoxicity of
MERS-CoV-infected cells was reduced by resveratrol treat-
ment (250 μM) to approximately 25% (Fig. 1c). Therefore,
we conclude that resveratrol reduced the cell death caused
by MERS-CoV infection.
Resveratrol reduced the RNA expression and viral yield of
MERS-CoV
To determine if resveratrol directly inhibits MERS-CoV in-
fection, we assessed the effects of resveratrol on MERS-CoV
viral production at the RNA level. We collected cell samples
with or without viral infection after resveratrol treatments at
24 and 48 hours post-infection (h.p.i). Extracted total RNA
was subjected to quantitative real-time PCR to compare the
relative MERS-CoV RNA levels. Shown in Fig. 2a, the
MERS-CoV RNA levels in resveratrol-treated cells at con-
centrations of 250, 200, 150, 62.5, and 31.25 μM were
significantly lower than in MERS-CoV-infected cells at
24 h.p.i. However, the inhibitory effects of low concen-
trations of resveratrol, including 62.5 and 31.25 μM, di-
minished at 48 h.p.i. This data suggests that resveratrol
treatment suppressed MERS-CoV RNA replication, al-
though it requires relatively high concentrations of res-
veratrol to deliver persisted antiviral effects.
Next, we determined the infectious titer of MERS-
CoV after resveratrol treatments by plaque reduction as-
says. Data in Fig. 2b showed that MERS titers were sig-
nificantly reduced by resveratrol treatment at 250, 200
and 150 μM respectively, at 48 h.p.i. This result is con-
sistent with those obtained from the quantitative real-
time PCR at 48 h.p.i. In summary, these findings indicate
that treatment of cells with resveratrol reduced the
MERS-Cov RNA levels and infectious titers, which pre-
sumably accounted for the observed decrease in cell
death.
Resveratrol inhibited existing MERS-CoV infection
Previous studies have shown that resveratrol exerted
antiviral activities by blocking NF-κB pathway [22, 30],
Fig. 1 Resveratrol reduced the cell death caused by MERS-CoV infection. Vero E6 cells were infected by MERS-CoV with M.O.I of 0.1 and treated
with resveratrol for 48 hours. The level of cell viability was determined by (a) MTS assay (b) neutral red uptake assay, and (c) LDH assay.
d Resveratrol itself caused limited cytotoxicity to Vero cells by LDH assay
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Fig. 2 Resveratrol decreased MERS-CoV RNA and viral plaques. a MERS RNA level was monitored at 24 and 48 h.p.i. by real-time PCR after resveratrol
treatment. Relative RNA levels were determined by comparing MERS only groups at each time point. GAPDH RNA was used as an internal control.
b Quantification of plaque reduction assay of MERS-CoV titer after treated with resveratrol from 250 μM to 31.25 μM for 48 hours
Fig. 3 Resveratrol inhibited the existing MERS infection. Resveratrol and MERS-CoV were simultaneously added into cells for first 3 hours before
removing virus and adding new resveratrol for the rest incubating time (a). MERS-CoV infected Vero cells for first 3 hours before washed out and
treated with resveratrol (b). The trends of cell proliferation by MTT assays (c and d) and MERS-CoV titers by plaque assays (e) were similar, revealing
resveratrol inhibited MERS viral yield even if existing MERS infection
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suggesting resveratrol has a broad spectrum of antiviral
effects by down-regulating inflammatory signaling trans-
duction. To determine whether resveratrol inhibits the
entry or a post-entry step of MERS-Cov infection, we
added resveratrol together with MERS-CoV immediately
for 3 hours or after the infection has been initiated
(Fig. 3a and b). We measured the cell proliferation
(Fig. 3c and d) and determined the viral titers in the su-
pernatants (Fig. 3e). The results demonstrated that even
when resveratrol was given after MERS-CoV infection, it
still reduced the viral titer. The same observations were
made when cell proliferations and viral titers were mea-
sured, suggesting that resveratrol inhibits MERS-CoV in-
fection after entry.
Resveratrol inhibited MERS-CoV nucleocapsid expression
To corroborate our findings, we stained nuclecapsid (N)
protein of MERS-CoV after resveratrol treatments at
24 h.p.i and visualized the N protein distribution by con-
focal microscopy. Images shown in Fig. 4a demonstrated
that 250 μM of resveratrol eliminated the N protein
fluorescent signal compared to control groups, while
150 μM of resveratrol exhibited a limited decreasing of
N protein signal. In order to elucidate whether the
strength of N protein signal was correlated to the con-
centration of resveratrol, we performed intracellular
staining of N protein in cells cultured in multiple well
plates. MERS-infected Vero E6 cells were fixed and per-
meablized to facilitate anti-N primary antibody to access
Fig. 4 Resveratrol reduced nucleocapsid expression of MERS-CoV. Vero E6 cells were infected by MERS-CoV (M.O.I. 0.1) and treated with resveratrol
for 24 hours followed by 4% paraformaldehyde fixation for immunofluorescent assays. a Nucleocapsid expressions were examined with confocal
microscope at 680× magnification. DAPI was used for nucleus staining. b Intracellular staining of MERS nucleocapsid expressions were visualized
by Odyssey® CLx Imaging system. c Quantification results of fluorescent intensities of MERS nucleocapsid proteins were determined by Odyssey®
CLx Imaging software
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the target protein and quantified the strength of fluores-
cence by Li-Cor imaging system (Fig. 4b and c). The re-
sults showed that resveratrol remarkably inhibited
MERS nucleocapsid protein translation in a dose-
dependent manner, especially in the concentration of
250 to 125 μM.
Resveratrol inhibited Caspase 3 cleavage induced by
MERS-CoV infection
Apoptosis in different tissues during MERS-CoV infec-
tion has been widely documented [31, 32]. We therefore
tested whether resveratrol is able to reduce the apoptosis
induced by MERS-CoV. Due to the cleavage of Caspase
3, an indicator of apoptosis, was reportedly elevated dur-
ing MERS-CoV infection [33], we collected the cell
lysates after MERS-CoV infection and resveratrol treat-
ments at 24 and 48 h.p.i. and conducted western blotting
to measure the Caspase 3 cleavage levels. The results
(Fig. 5) show that the protein expression of the cleaved
Caspase 3 significantly increased after MERS-CoV infec-
tion, confirming that MERS-CoV could cause cellular
apoptosis. Interestingly, when resveratrol was added, the
levels of Caspase 3 cleavage decreased. As the concen-
tration of resveratrol went higher, the levels of Caspase 3
cleavage decreased in a dose-dependent manner (Fig. 5c).
Our results suggest that resveratrol reduced the MERS-
CoV-mediated apoptosis. Notably, resveratrol at 250 μM
did not lower the Caspase 3 cleavage to the same level,
as did 200 μM (Fig. 5a, c). Given to the cytotoxicity of
resveratrol itself, this result is expected.
Consecutively administration of resveratrol at lower
concentrations inhibited MERS infection
From the qPCR (Fig. 2a) and western blotting results
(Fig. 5), we noticed that resveratrol at 62.5 μM and
below appeared to inhibit MERS-CoV within 24 hours
but then lost effects at 48 h.p.i. The loss of inhibitory ef-
fects at 48 hrs could due to the degradation of resvera-
trol in the media after such long period of incubation.
Given the high dosages of resveratrol still has some cyto-
toxicity (Fig. 1e), lower dosages are more desirable to
treat MERS-infected patients clinically. To explore the
possibility of utilization of resveratrol at lower dosages,
we added resveratrol consecutively (every 24 hrs) to
MERS-infected cells at lower concentrations and evalu-
ated the cell proliferation, cell viability, and cytotoxicity
(Fig. 6). Interestingly, consecutive addition of resveratrol
at 62.5 μM but not 31.25 μM or below partially rescued
MERS-Cov-induced cell death (Fig. 6a-c) and lowered
the production of infectious MERS-CoV by approximate
tenfold (Fig. 6d), indicating resveratrol can inhibit
MERS-CoV by administrating at lower dosages if given
consecutively.
Fig. 5 Resveratrol reduced MERS-induced cell apoptosis. Vero E6 cells were infected by MERS-CoV at M.O.I. of 0.1 and treated with resveratrol for
24 and 48 hours before collecting protein lysates. a Protein expression levels of MERS nucleocapsid and cleaved caspase 3 were evaluated by
western blotting. GAPDH was used as a loading control. b and c Protein expression levels were quantified and then normalized with GAPDH
expression. MERS nucleocapsid as well as cleaved Caspase 3 expressions were reduced by resveratrol in a dose-dependent manner
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Resveratrol exhibited extended antiviral activities
Furthermore, we tested the effects of resveratrol on an-
other emerging positive-sense RNA virus, chikungunya
virus. As shown in Fig. 7, resveratrol not only inhibited
MERS-CoV viral production but also reduced the pro-
duction of chikungunya virus at concentrations of 250
and 125 μM. Altogether, our data suggests that resvera-
trol might be a lead candidate for further pre-clinical as-
sessments of antiviral activity for MERS-CoV and
additional emerging RNA viruses.
Discussion
As an emerging human viral pathogen, MERS-CoV in-
fection causes devastating diseases due to its high mor-
tality. Therefore, it is urgent to develop vaccine or
therapeutics. During the outbreak of Severe Acute
Respiratory Syndrome (SARS) in 2002–2003, several
antimicrobial agents were used to treat SARS-infected
patients, including ribavirin, lopinavir/ritonavir, and type
I interferon. However, most of the medication regimes
showed no significant efficacy to SARS and came along
with side effects, such as renal dysfunction or hemolytic
anemia caused by ribavirin [34]. During the MERS-CoV
epidemic, these treatments provided none or limited
improvement in survival of patients and the efficacy re-
mains unclear [35–37]. As a result, there is no effective
remedial candidate during the MERS-CoV epidemic. In
this study, we report the anti-MERS-CoV activities of
resveratrol in vitro, providing evidence to support fur-
ther detailed examinations of the potential clinical bene-
fits for resveratrol in MERS-CoV infections.
We acknowledged that it is necessary to validate the
anti-MERS efficacy of resveratrol in vivo. However,
most of experimental animals, including rabbits, mice
and ferrets, are asymptomatic after MERS infection
[38–40]. Since the dipeptidyl peptidase 4 (DPP4) is a
crucial receptor of MERS-CoV [41], we hypothesize
that the human DPP4 expressed mice [42] could be a
suitable model for examining the anti-MERS activity of
resveratrol in the future.
Resveratrol itself has minor cytotoxicity even at high
concentration of 250 μM, but it can be neglected com-
paring with the toxic levels caused by MERS-CoV infec-
tion, which were much greater than that of resveratrol
itself. Considering the robust cell death caused by
MERS-CoV, we think that resveratrol treatment remains
a viable therapeutic strategy. In our study, we have
shown that the resveratrol can be given either at high
dosages up to 250 μM or at a relatively low concentra-
tion, such as 62.5 μM consecutively to treat MERS-CoV-
infected cells.
In terms of the possible antiviral mechanisms for res-
veratrol, resveratrol has been reported to activate ERK1/
2 signaling pathway [43] and promote cell proliferation
and enhance SIR1 signaling [44], both of which are re-
lated to cellular survival and DNA repair in response to
Fig. 6 Consecutively resveratrol administration inhibited MERS infection in a lower dosage. MERS-infected Vero E6 cells were treated with resvera-
trol in lower dosages every 24 hours. The cell proliferation by MTT assay (a), cell viability by NRU assay (b), cytotoxicity by LDH assay (c), and
plaque assay (d) were utilized to measure the cell survival after 48 hours of MERS infection at M.O.I. of 0.1
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DNA damage [45, 46]. On the other hand, resveratrol
could counteract the MERS-CoV-induced apoptosis by
down-regulating FGF-2 signaling [47, 48]. In addition,
MERS-CoV infection could lead to the production of in-
flammatory cytokines [49] whereas resveratrol may re-
duce the inflammation by interfering with the NF-κB
pathway [50, 51]. In our study, the levels of cleaved
caspase 3 were reduced by reseveratol after MERS-CoV
infection. These changes may be results of direct inhib-
ition of caspase 3 cleavage by resvertion of cell survival
and the reduction of virus-induced apoptosis by resvera-
trol or inhibition of an upstream event that is required
for caspase 3 cleavage. While the exact mechanism
needs further investigation, the observed anti-MERS-
CoV effect appears to be a collective result of the pro-
motion of cell survival and the reduction of virus-
induced apoptosis by resveratrol.
Conclusion
In our study, we firmly found that resveratrol alone in-
hibits MERS-CoV infection. Future study will evaluate
the potential synergy between resveratrol and other po-
tential anti-MERS-CoV compounds to treat MERS-CoV
infections.
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